5 days ago · PLAINSBORO, N.J., Jan. 28, 2025 /PRNewswire/ -- Novo Nordisk today announced that the U.S. Food and Drug Administration (FDA) has approved Ozempic ® to reduce the risk …

4 days ago · Novo Nordisk is conducting a different study to understand how and why semgalutide seems to reduce the progression of kidney disease, said Stephen Gough, global …

5 days ago · Type 2 diabetes is a leading cause of chronic kidney disease, which affects more than one in seven U.S. adults. ... As more people seek out Ozempic, though, Novo Nordisk …

4 days ago · The FDA has approved Novo Nordisk's diabetes drug Ozempic to help reduce the risk of worsening kidney disease, kidney failure, and heart-related death in adults with type 2 …

4 days ago · The U.S. FDA has approved Novo Nordisk's Ozempic for reducing the risk of kidney failure and disease progression, as well as death due to heart problems in diabetes patients …

4 days ago · The approval was based on data from a late-stage study, which showed that Ozempic helped cut the risk of death from chronic kidney disease and major cardiac events by …

May 24, 2024 · Semaglutide reduced the risk of clinically important kidney outcomes and death from cardiovascular causes in patients with type 2 diabetes and chronic kidney disease. …

Jun 24, 2024 · Semaglutide 1 mg demonstrated a statistically significant and superior reduction of 24% in the risk of kidney disease-related events vs. placebo in adults with type 2 diabetes and …

3 days ago · The FDA has approved Novo Nordisk’s Ozempic (semaglutide) as the first and only GLP-1 receptor agonist (GLP-1 RA) indicated to reduce the risk of worsening kidney disease, …

Ozempic, or semaglutide, can now be used to reduce the risk of worsening kidney disease or kidney failure in adults with type 2 diabetes and chronic kidney disease, Novo Nordisk said.